Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.

Fiche publication

Date publication

novembre 2018

Journal

Gynecologic oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr KALBACHER Elsa

Tous les auteurs :
Romeo C, Joly F, Ray-Coquard I, El Kouri C, Mercier-Blas A, Berton-Rigaud D, Kalbacher E, Cojocarasu O, Fabbro M, Cretin J, Zannetti A, Abadie-Lacourtoisie S, Mollon D, Hardy-Bessard AC, Provansal M, Blot E, Delbaldo C, Lesoin A, Freyer G, You B

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30446275

Résumé

Carboplatin and pegylated liposomal doxorubicin combination is a standard regimen in platinum-sensitive recurrent ovarian cancer patients. The pegylated liposomal doxorubicin shortage from 2011 to 2013 urged assessment of the efficacy and tolerance of non-pegylated liposomal doxorubicin in combination with carboplatin.

Mots clés

Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Carboplatin, administration & dosage, Doxorubicin, administration & dosage, Female, Humans, Middle Aged, Ovarian Neoplasms, drug therapy, Polyethylene Glycols, administration & dosage, Prospective Studies